Nature Communications (Apr 2019)
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
- Jordi Bertran-Alamillo,
- Valérie Cattan,
- Marie Schoumacher,
- Jordi Codony-Servat,
- Ana Giménez-Capitán,
- Frédérique Cantero,
- Mike Burbridge,
- Sonia Rodríguez,
- Cristina Teixidó,
- Ruth Roman,
- Josep Castellví,
- Silvia García-Román,
- Carles Codony-Servat,
- Santiago Viteri,
- Andrés-Felipe Cardona,
- Niki Karachaliou,
- Rafael Rosell,
- Miguel-Angel Molina-Vila
Affiliations
- Jordi Bertran-Alamillo
- Laboratory of Oncology, Pangaea Oncology, Quiron Dexeus University Hospital
- Valérie Cattan
- Institut de Recherches Internationales Servier
- Marie Schoumacher
- Institut de Recherches Internationales Servier
- Jordi Codony-Servat
- Laboratory of Oncology, Pangaea Oncology, Quiron Dexeus University Hospital
- Ana Giménez-Capitán
- Laboratory of Oncology, Pangaea Oncology, Quiron Dexeus University Hospital
- Frédérique Cantero
- Institut de Recherches Internationales Servier
- Mike Burbridge
- Institut de Recherches Internationales Servier
- Sonia Rodríguez
- Laboratory of Oncology, Pangaea Oncology, Quiron Dexeus University Hospital
- Cristina Teixidó
- Laboratory of Oncology, Pangaea Oncology, Quiron Dexeus University Hospital
- Ruth Roman
- Laboratory of Oncology, Pangaea Oncology, Quiron Dexeus University Hospital
- Josep Castellví
- Laboratory of Oncology, Pangaea Oncology, Quiron Dexeus University Hospital
- Silvia García-Román
- Laboratory of Oncology, Pangaea Oncology, Quiron Dexeus University Hospital
- Carles Codony-Servat
- Laboratory of Oncology, Pangaea Oncology, Quiron Dexeus University Hospital
- Santiago Viteri
- Instituto Oncológico Dr. Rosell, Quiron-Dexeus University Hospital
- Andrés-Felipe Cardona
- Clinical and Translational Oncology Group, Institute of Oncology, Fundacion Santa Fe de Bogotá
- Niki Karachaliou
- Instituto Oncológico Dr. Rosell, Quiron-Dexeus University Hospital
- Rafael Rosell
- Laboratory of Oncology, Pangaea Oncology, Quiron Dexeus University Hospital
- Miguel-Angel Molina-Vila
- Laboratory of Oncology, Pangaea Oncology, Quiron Dexeus University Hospital
- DOI
- https://doi.org/10.1038/s41467-019-09734-5
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 14
Abstract
Non-small cell lung cancer with EGFR mutations are known to develop resistance to EGFR tyrosine kinase inhibitors. Here, the authors show AURKB activation to be associated with resistance in EGFR mutant lung cancer cells, and that AURKB is a therapeutic target in resistant tumours that lack the p.T790M or other acquired mutations.
